Taken together, the preclinical data validate PDE10A as a potential target for therapeutic intervention (Grauer et al. 2009; Kehler and Nielsen 2011), and support further investigation of the safety, tolerability, and potential multidimensional efficacy of selective PDE10A inhibitors in people with schizophrenia (Heckman et al. 2016). The gene discussed is PDE10A; the disease is schizophrenia.